Tags

Type your tag names separated by a space and hit enter

Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.
Am J Trop Med Hyg. 2013 May; 88(5):954-961.AJ

Abstract

Yellow fever (YF) vaccine-associated serious adverse events and changing YF epidemiology have challenged healthcare providers to vaccinate only travelers whose risk of YF during travel is greater than their risk of adverse events. We describe the travel characteristics and YF vaccine use among US travelers visiting Global TravEpiNet clinics from January of 2009 to March of 2011. Of 16,660 travelers, 5,588 (34%) had itineraries to areas with risk of YF virus transmission. Of those travelers visiting one country with YF risk (N = 4,517), 71% were vaccinated at the visit, and 20% were presumed to be immune from prior vaccination. However, travelers visiting friends and relatives (odds ratio [OR] = 2.57, 95% confidence interval [95% CI] = 1.27-5.22) or going to Nigeria (OR = 3.01, 95% CI = 1.37-6.62) were significantly more likely to decline vaccination. To optimize YF vaccine use, clinicians should discuss an individual's risk-benefit assessment of vaccination and close knowledge gaps regarding vaccine use among at-risk populations.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

23458961

Citation

Jentes, Emily S., et al. "Travel Characteristics and Yellow Fever Vaccine Usage Among US Global TravEpiNet Travelers Visiting Countries With Risk of Yellow Fever Virus Transmission, 2009-2011." The American Journal of Tropical Medicine and Hygiene, vol. 88, no. 5, 2013, pp. 954-961.
Jentes ES, Han P, Gershman MD, et al. Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011. Am J Trop Med Hyg. 2013;88(5):954-961.
Jentes, E. S., Han, P., Gershman, M. D., Rao, S. R., LaRocque, R. C., Staples, J. E., Ryan, E. T., & The Global TravEpiNet Consortium, . (2013). Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011. The American Journal of Tropical Medicine and Hygiene, 88(5), 954-961. https://doi.org/10.4269/ajtmh.12-0463
Jentes ES, et al. Travel Characteristics and Yellow Fever Vaccine Usage Among US Global TravEpiNet Travelers Visiting Countries With Risk of Yellow Fever Virus Transmission, 2009-2011. Am J Trop Med Hyg. 2013;88(5):954-961. PubMed PMID: 23458961.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011. AU - Jentes,Emily S, AU - Han,Pauline, AU - Gershman,Mark D, AU - Rao,Sowmya R, AU - LaRocque,Regina C, AU - Staples,J Erin, AU - Ryan,Edward T, AU - The Global TravEpiNet Consortium,, Y1 - 2013/03/04/ PY - 2013/3/6/entrez PY - 2013/3/6/pubmed PY - 2013/7/6/medline SP - 954 EP - 961 JF - The American journal of tropical medicine and hygiene JO - Am J Trop Med Hyg VL - 88 IS - 5 N2 - Yellow fever (YF) vaccine-associated serious adverse events and changing YF epidemiology have challenged healthcare providers to vaccinate only travelers whose risk of YF during travel is greater than their risk of adverse events. We describe the travel characteristics and YF vaccine use among US travelers visiting Global TravEpiNet clinics from January of 2009 to March of 2011. Of 16,660 travelers, 5,588 (34%) had itineraries to areas with risk of YF virus transmission. Of those travelers visiting one country with YF risk (N = 4,517), 71% were vaccinated at the visit, and 20% were presumed to be immune from prior vaccination. However, travelers visiting friends and relatives (odds ratio [OR] = 2.57, 95% confidence interval [95% CI] = 1.27-5.22) or going to Nigeria (OR = 3.01, 95% CI = 1.37-6.62) were significantly more likely to decline vaccination. To optimize YF vaccine use, clinicians should discuss an individual's risk-benefit assessment of vaccination and close knowledge gaps regarding vaccine use among at-risk populations. SN - 1476-1645 UR - https://www.unboundmedicine.com/medline/citation/23458961/Travel_characteristics_and_yellow_fever_vaccine_usage_among_US_Global_TravEpiNet_travelers_visiting_countries_with_risk_of_yellow_fever_virus_transmission_2009_2011_ L2 - https://ajtmh.org/doi/10.4269/ajtmh.12-0463 DB - PRIME DP - Unbound Medicine ER -